46000 Federal Register / Vol. 86, No. 156 / Tuesday, August 17, 2021 / Notices 

injury, condition, or death described in 

the petition is due to factors unrelated 

to the administration of the vaccine 

described in the petition,’’ and 

2. Any allegation in a petition that the 

petitioner either: 

a. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition not set forth in the 

Vaccine Injury Table but which was 

caused by’’ one of the vaccines referred 

to in the Table, or 

b. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition set forth in the 

Vaccine Injury Table the first symptom 

or manifestation of the onset or 

significant aggravation of which did not 

occur within the time period set forth in 

the Table but which was caused by a 

vaccine’’ referred to in the Table. 

In accordance with Section 

2112(b)(2), all interested persons may 

submit written information relevant to 

the issues described above in the case of 

the petitions listed below. Any person 

choosing to do so should file an original 

and three (3) copies of the information 

with the Clerk of the United States 

Court of Federal Claims at the address 

listed above (under the heading FOR

FURTHER INFORMATION CONTACT), with a 

copy to HRSA addressed to Director, 

Division of Injury Compensation 

Programs, Healthcare Systems Bureau, 

5600 Fishers Lane, 08N146B, Rockville, 

Maryland 20857. The Court’s caption 

(Petitioner’s Name v. Secretary of HHS) 

and the docket number assigned to the 

petition should be used as the caption 

for the written submission. Chapter 35 

of title 44, United States Code, related 

to paperwork reduction, does not apply 

to information required for purposes of 

carrying out the Program. 

Diana Espinosa, 

Acting Administrator. 

List of Petitions Filed 

1. James Edward Perry, Garden Grove, 

California, Court of Federal Claims No: 

21–1530V 

2. Billy Sword, Kingsport, Tennessee, Court 

of Federal Claims No: 21–1534V 

3. Amanda Purdin, Hilliard, Ohio, Court of 

Federal Claims No: 21–1536V 

4. Eileen Arcery, Depew, New York, Court of 

Federal Claims No: 21–1537V 

5. Alex Dosser, Oklahoma City, Oklahoma, 

Court of Federal Claims No: 21–1538V 

6. Rameen Rizi, Phoenix, Arizona, Court of 

Federal Claims No: 21–1544V 

7. Angeline Khan on behalf of A.K., 

Hayward, California, Court of Federal 

Claims No: 21–1545V 

8. Veronica Mendoza, Juarez, Mexico, Court 

of Federal Claims No: 21–1547V 

9. Jennifer Raftery, Washington, District of 

Columbia, Court of Federal Claims No: 

21–1549V 

10. Meagan Brown Schmidt, Washington, 

District of Columbia, Court of Federal 

Claims No: 21–1550V 

11. David Shafer, Midland, Texas, Court of 

Federal Claims No: 21–1552V 

12. Darcy Weidner, Sharon, Pennsylvania, 

Court of Federal Claims No: 21–1554V 

13. Olinda Gilmore, Universal City, Texas, 

Court of Federal Claims No: 21–1556V 

14. William L. Miller, Cary, North Carolina, 

Court of Federal Claims No: 21–1559V 

15. Erik Koonce, Doylestown, Pennsylvania, 

Court of Federal Claims No: 21–1560V 

16. Patricia Santiago, Chicago, Illinois, Court 

of Federal Claims No: 21–1562V 

17. Nicholas Politano, Phoenix, Arizona, 

Court of Federal Claims No: 21–1563V 

18. Laura Surface, Northfield, New Jersey, 

Court of Federal Claims No: 21–1565V 

19. Juanita Green, Washington, District of 

Columbia, Court of Federal Claims No: 

21–1566V 

20. Claire Kuang, Washington, District of 

Columbia, Court of Federal Claims No: 

21–1567V 

21. Kathleen R. McNamee, North Olmstead, 

Ohio, Court of Federal Claims No: 21– 

1568V 

22. Katie Perette, Bridgewater, 

Massachusetts, Court of Federal Claims 

No: 21–1569V 

23. John Wirsen, Springfield, Missouri, Court 

of Federal Claims No: 21–1571V 

24. Raquel Hernandez, Modesto, California, 

Court of Federal Claims No: 21–1572V 

25. Hannah R. Boudreau, Juliet, Tennessee, 

Court of Federal Claims No: 21–1573V 

26. Beverly Hales, Ashland, Texas, Court of 

Federal Claims No: 21–1575V 

27. William McCaughey, Warwick, Rhode 

Island, Court of Federal Claims No: 21– 

1576V 

28. Helena Smith on behalf of A.S., Chicago, 

Illinois, Court of Federal Claims No: 21– 

1577V 

29. William Minner, Topeka, Kansas, Court 

of Federal Claims No: 21–1579V 

30. Keith A. Lee, New York, New York, Court 

of Federal Claims No: 21–1582V 

31. Bobbi Hoodiman on behalf of T.H., 

Ridgewood, New Jersey, Court of Federal 

Claims No: 21–1583V 

32. Edward O. Janosko, II, Wilmington, North 

Carolina, Court of Federal Claims No: 

21–1584V 

33. Jammie Yerks, Boscobel, Wisconsin, 

Court of Federal Claims No: 21–1585V 

34. Dennis L. Ericson, West Hartford, 

Connecticut, Court of Federal Claims No: 

21–1587V 

35. Todd Seely, Washington, District of 

Columbia, Court of Federal Claims No: 

21–1590V 

36. Kathleen Pachuki, Chicago, Illinois, Court 

of Federal Claims No: 21–1591V 

37. Madison Jugon, The Woodlands, Texas, 

Court of Federal Claims No: 21–1592V 

38. Brenda Hatten, Omaha, Nebraska, Court 

of Federal Claims No: 21–1593V 

39. Cristian Garcia, Boston, Massachusetts, 

Court of Federal Claims No: 21–1601V 

40. Robert Donchess, Blythewood, South 

Carolina, Court of Federal Claims No: 

21–1603V 

41. Luke Kramer, Upland, California, Court of 

Federal Claims No: 21–1604V 

42. James Mease, Elkton, Maryland, Court of 

Federal Claims No: 21–1605V 

43. Taylor Williams, Greensboro, North 

Carolina, Court of Federal Claims No: 

21–1606V 

44. Frank Burke, Portland, Oregon, Court of 

Federal Claims No: 21–1607V 

45. Paul Pellegrino on behalf of A.P., 

Matthews, North Carolina, Court of 

Federal Claims No: 21–1608V 

46. Victoria A. Van Voorhis, Rochester, New 

York, Court of Federal Claims No: 21– 

1610V 

47. Edna Fowler on behalf of The Estate of 

William Fowler, Deceased, Dublin, Ohio, 

Court of Federal Claims No: 21–1611V 

48. Morgan Smith, Rock Hill, South Carolina, 

Court of Federal Claims No: 21–1613V 

49. Roger Nyhuis, Cincinnati, Ohio, Court of 

Federal Claims No: 21–1615V 

50. Julia Seeli on behalf of P.S., Phoenix, 

Arizona, Court of Federal Claims No: 21– 

1616V 

51. Michelle Foster on behalf of H.F., 

Phoenix, Arizona, Court of Federal 

Claims No: 21–1617V 

52. Nicholas Delaney and Krystal Delaney on 

behalf of C.M.D., St. Cloud, Minnesota, 

Court of Federal Claims No: 21–1620V 

53. Cassie Malone, Casper, Wyoming, Court 

of Federal Claims No: 21–1625V 

54. Sarah Lukas, Phoenix, Arizona, Court of 

Federal Claims No: 21–1627V 

55. Jeanne M. Quattromani, Westerly, Rhode 

Island, Court of Federal Claims No: 21– 

1628V 

56. Linda Waxman, Lyndhurst, Ohio, Court 

of Federal Claims No: 21–1631V 

57. John D. Slusser, Jr., St. Christiansburg, 

Virginia, Court of Federal Claims No: 21– 

1636V 

58. Julia Seeli on behalf of S. H., Phoenix, 

Arizona, Court of Federal Claims No: 21– 

1637V 

59. Yvonne Romo, Seattle, Washington, Court 

of Federal Claims No: 21–1638V 

[FR Doc. 2021–17557 Filed 8–16–21; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Request for Information: Comments on 

the National Institute of Diabetes and 

Digestive and Kidney Diseases 

(NIDDK) Draft Strategic Plan 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: This Request for Information 

(RFI) is intended to seek feedback from 

the public on the draft National Institute 

of Diabetes and Digestive and Kidney 

Diseases (NIDDK) Strategic Plan for 

Research. NIDDK invites input from: 

The scientific research community; 

patients and caregivers; health care 

providers and health advocacy 

organizations; scientific and 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 156 / Tuesday, August 17, 2021 / Notices 46001 

professional organizations; federal 

agencies; and other stakeholders, 

including interested members of the 

public. Organizations are strongly 

encouraged to submit a single response 

that reflects the views of their 

organization and their membership as a 

whole. 

DATES: Comments must be received by 

11:59:59 p.m. (ET) on August 31, 2021 

to ensure consideration. 

ADDRESSES: All comments must be 

submitted electronically on the 

submission website, available at https:// 

rfi.grants.nih.gov/?s=60fef9beab

43000053007ed2. 

FOR FURTHER INFORMATION CONTACT: 

Please direct all inquiries to: Lisa 

Gansheroff, NIDDKstrategicplan@

nih.gov, 301–496–6623. 

SUPPLEMENTARY INFORMATION: This 

Notice is in accordance with the 21st 

Century Cures Act, NIH institutes are 

required to regularly update their 

strategic plans. The NIDDK’s ongoing 

Institute-wide strategic planning process 

will develop a broad vision for 

accelerating research into the causes, 

prevention, and treatment of diseases 

and conditions within the Institute’s 

mission. This overarching trans-NIDDK 

Strategic Plan will complement 

NIDDK’s disease-specific planning 

efforts. The Strategic Plan will have a 5- 

year time horizon but will also include 

planning for longer term efforts that 

could be initiated within this time 

frame. 

External input has been integral to the 

strategic planning process. NIDDK 

established a Working Group of Council, 

comprised of 44 external scientists and 

patient advocates, including a subset of 

the members of NIDDK’s Advisory 

Council and others with expertise across 

the range of NIDDK’s mission areas. The 

Institute also invited broad external 

input with a public RFI in 2020, and 

received valuable comments from 

organizations, individual researchers, 

people living with diseases in NIDDK’s 

mission, and others. Based on input 

from the Working Group, the previous 

RFI, and Council, the Institute has 

prepared a draft of the Strategic Plan; 

the draft will be available for public 

comment through August 31, 2021 via 

the new RFI at the link above. 

NIDDK is committed to empowering a 

multidisciplinary research community; 

engaging diverse stakeholders; and 

leveraging discoveries of connections 

among diseases across NIDDK’s mission 

to improve prevention, treatment, and 

health equity—pursuing pathways to 

health for all. This theme is addressed 

throughout the draft strategic plan. 

The draft Strategic Plan includes five 

major sections: 

• Advance understanding of 

biological pathways and environmental 

contributors to health and disease 

• Advance pivotal clinical studies 

and trials for prevention, treatment, and 

cures in diverse populations 

• Advance research to disseminate 

and implement evidence-based 

prevention strategies and treatments in 

clinics and community settings, to 

improve the health of all people, more 

rapidly and more effectively 

• Advance stakeholder engagement— 

including patients and other 

participants as true partners in research 

• Promote efficient and effective ways 

to serve as a trusted steward of public 

resources and support research for 

diseases across our mission 

NIDDK invites comments on the draft 

Strategic Plan from: The scientific 

research community; patients and 

caregivers; health care providers and 

health advocacy organizations; scientific 

and professional organizations; federal 

agencies; and other stakeholders, 

including interested members of the 

public. Organizations are strongly 

encouraged to submit a single response 

that reflects the views of their 

organization and membership as a 

whole. 

Responses to this RFI are voluntary 

and may be submitted anonymously. 

Please do not include any information 

that you do not wish to make public. 

Proprietary, classified, confidential, or 

sensitive information should not be 

included in your response. The 

Government will use the information 

submitted in response to this RFI at its 

discretion. Individual feedback will not 

be provided to any responder. The 

Government reserves the right to use 

any submitted information on public 

websites, in reports, in summaries of the 

state of the science, in any possible 

resultant solicitation(s), grant(s), or 

cooperative agreement(s), or in the 

development of future funding 

opportunity announcements. This RFI is 

for informational and planning purposes 

only and is not a solicitation for 

applications or an obligation on the part 

of the Government to provide support 

for any ideas identified in response to 

it. Please note that the Government will 

not pay for the preparation of any 

information submitted or for use of that 

information. NIDDK looks forward to 

your input and we hope that you will 

share this RFI with your colleagues. 

Dated: August 11, 2021. 

Bruce Tibor Roberts, 

Health Science Policy Analyst, Office of 

Scientific Program and Policy Analysis, 

National Institute of Diabetes and Digestive 

and Kidney Diseases, National Institutes of 

Health. 

[FR Doc. 2021–17535 Filed 8–16–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Clinical Trials and 

Comparative Effectiveness Studies. 

Date: August 23, 2021. 

Time: 10:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Shanta Rajaram, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH, NSC, 6001 Executive Blvd., 

Suite 3208, MSC 9529, Bethesda, MD 20892, 

(301) 435–6033, rajarams@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: August 11, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–17559 Filed 8–16–21; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES